The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has officially approved a new, higher-dose Wegovy pen, enabling users to administer the maximum 7.2mg dose of semaglutide in a single injection. This significant development streamlines the treatment process for individuals prescribed Wegovy for weight loss or weight management, eliminating the need for three separate 2.4mg injections at a time.

Manufactured by Novo Nordisk, the new single-dose device is expected to be rolled out across the UK within the next four to six weeks. While the MHRA had already approved the 7.2mg dose in January, this latest ruling specifically sanctions the new pen, which features an automatic dosing mechanism that locks after use. This practical change is anticipated to enhance convenience and potentially make weight-loss treatment more accessible for eligible patients.

Sebnem Avsar Tuna, general manager at Novo Nordisk, welcomed the MHRA's decision, stating that it provides an additional administration option for UK patients on the 7.2mg once-weekly maintenance dose. He emphasized the company's commitment to collaborating with healthcare professionals and partners to facilitate its introduction in alignment with local prescribing guidelines. Mr. Tuna further highlighted that this approval represents an important step in supporting people living with obesity, offering healthcare professionals greater flexibility to tailor treatment and improve health outcomes.

The approval follows robust findings from the STEP UP clinical trial, which demonstrated the efficacy of the stronger dose. Adults treated with the 7.2mg dose, when combined with a healthy diet and regular exercise, achieved an average weight loss of up to 20.7 percent. Notably, approximately one-third of participants, all classified as clinically obese with a BMI over 30, experienced weight loss of 25 percent or more after 72 weeks. In stark contrast, those administered a placebo drug lost only 1.4 percent of their baseline bodyweight. Further analysis from the trial indicated that the higher 7.2mg once-weekly dose could be particularly beneficial for individuals who have plateaued on the 2.4mg maintenance dose for at least four weeks.

Despite the promising clinical results and the convenience of the new device, some obesity experts have urged caution. Concerns have been raised regarding the significant dose increase from 2.4mg to 7.2mg, with experts suggesting that while there might be a marginal extra benefit, many patients might not tolerate such a high dose due to potential side effects. Common side effects reported during trials included gastrointestinal issues, such as nausea, primarily occurring during the dose escalation phase from the standard 0.25mg starting dose to 7.2mg. Furthermore, experts predict that uptake of the highest dose might be low due to its cost and potential side-effects, given that the current top dose is already expensive.

Semaglutide, marketed as Ozempic for diabetes and Wegovy for weight loss, has been lauded as a significant breakthrough in combating obesity. However, broader concerns persist regarding its long-term implications, including potential supply and demand issues. Some experts also warn that the benefits might be short-lived once treatment concludes, suggesting that millions might need to remain on the injections indefinitely to maintain weight loss.

For patients, the new device will initially be available on private prescription. It will need to undergo a review by the National Institute for Health and Care Excellence (NICE) to assess its cost-effectiveness before it can be widely rolled out on the NHS to eligible patients. The MHRA has advised all patients to strictly follow their prescriber's instructions and to consult their doctor if unsure. The agency also confirmed its ongoing review of Wegovy's safety and effectiveness and encourages anyone experiencing suspected side effects from the stronger dose to report them directly via the Yellow Card scheme.